#	Pagina
attuale pagina	/open-h2020/projects/196514/index.html

Opendata, web and dolomites

RETOXY

Clinical validation of retinal oximetry as a biomarker

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

RETOXY project word cloud

Explore the words cloud of the RETOXY project. It provides you a very rough idea of what is the project "RETOXY" about.

commercialisation report patients glaucoma retina feasibility earlier small eye progress gains considerable useable disease larger prevalence practise successful macular indicate degeneration ehf diabetic foundation tool business lay benefiting plan diseases oxygenation retinopathy sme disturbed societal groups validate market economic moving age oximeter clinical yield sight intervention serious retinal biomarker concurrent monitoring validated severity disturbance later create threatening individual oximetry oxymap

Project "RETOXY" data sheet

The following table provides information about the project.

Coordinator	OXYMAP EHF Organization address address: HAMRAHLIO 17 city: REYKJAVIK postcode: 105 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Iceland [IS]
Project website	http://www.oxymap.com/
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-1-2014
Funding Scheme	SME-1
Starting year	2015
Duration (year-month-day)	from 2015-05-01 to 2015-10-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	OXYMAP EHF OXYMAP EHF Organization address address: HAMRAHLIO 17 city: REYKJAVIK postcode: 105 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IS (REYKJAVIK)	coordinator	50˙000.00

Map

Project objective

Disturbance in oxygenation of the retina of the eye is believed to be involved in many sight-threatening diseases, such as diabetic retinopathy, glaucoma and age-related macular degeneration. Oxymap ehf (SME) has developed an oximeter to measure retinal oxygenation. The oximeter is already used by over 20 research groups and the results of small-scale studies indicate that the oximeter can measure disturbed oxygenation in various common and serious eye diseases.

The Oxymap oximeter is currently only useable for research and the aim of the phase 1 and 2 projects is to validate oximetry for clinical use. This will allow earlier intervention and better monitoring of disease progress, benefiting individual patients. Due to the high prevalence and severity of the diseases, societal and economic gains are also considerable. Moving retinal oximetry from being a research tool only to being a validated clinical biomarker will also create a much larger market for Oxymap.

The phase 1 project will yield a feasibility report, including a business plan. The project will lay the foundation for later uptake of retinal oximetry in clinical practise and the concurrent successful commercialisation.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RETOXY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RETOXY" are provided by the European Opendata Portal: CORDIS opendata.